GEP20063831B - Substituted bicyclic derivatives for treatment of abnormal cell growth - Google Patents
Substituted bicyclic derivatives for treatment of abnormal cell growthInfo
- Publication number
- GEP20063831B GEP20063831B GE5023A GEAP2001005023A GEP20063831B GE P20063831 B GEP20063831 B GE P20063831B GE 5023 A GE5023 A GE 5023A GE AP2001005023 A GEAP2001005023 A GE AP2001005023A GE P20063831 B GEP20063831 B GE P20063831B
- Authority
- GE
- Georgia
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- substituted bicyclic
- bicyclic derivatives
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21313600P | 2000-06-22 | 2000-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20063831B true GEP20063831B (en) | 2006-05-25 |
Family
ID=22793862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GE5023A GEP20063831B (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for treatment of abnormal cell growth |
Country Status (42)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| DK1117653T3 (da) | 1998-10-01 | 2003-05-26 | Astrazeneca Ab | Quinolin- og quinazolinderivater og deres anvendelse som inhibitorer af cykokin-merierede sygdomme |
| CN1330640C (zh) * | 2000-06-22 | 2007-08-08 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| EP1369418B1 (en) * | 2001-02-21 | 2010-07-28 | Mitsubishi Tanabe Pharma Corporation | Quinazoline derivatives |
| US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
| HUP0500117A3 (en) * | 2001-11-30 | 2008-03-28 | Pfizer Prod Inc | Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth |
| BR0214876A (pt) | 2001-12-12 | 2004-12-28 | Pfizer Prod Inc | Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer |
| WO2003049740A1 (en) * | 2001-12-12 | 2003-06-19 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP2280003B1 (en) * | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| JP4611745B2 (ja) | 2002-11-20 | 2011-01-12 | アレイ バイオファーマ、インコーポレイテッド | ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン |
| CN1729001A (zh) * | 2002-12-18 | 2006-02-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物 |
| WO2004056802A1 (en) * | 2002-12-19 | 2004-07-08 | Pfizer Products Inc. | Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
| CA2521348A1 (en) * | 2003-04-09 | 2004-10-21 | Pfizer Products Inc. | Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates |
| WO2004106308A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| AU2004253967B2 (en) * | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| EP1644017A2 (en) * | 2003-07-15 | 2006-04-12 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| WO2005016347A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| AU2004272348B2 (en) | 2003-09-16 | 2008-09-04 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| WO2005044302A1 (en) * | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CN1914182B (zh) | 2004-02-03 | 2011-09-07 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| MX2007000610A (es) | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina. |
| CN101010304A (zh) * | 2004-09-01 | 2007-08-01 | 三菱制药株式会社 | 分子伴侣功能调节剂 |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| EP2444421A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
| CA2610661A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| WO2006129168A2 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Bicyclic derivatives for the treatment of abnormal cell growth |
| GEP20125398B (en) | 2005-09-07 | 2012-02-27 | Amjen Freemont Ink | Human monoclonal antibodies to activin receptor-like kinase-1 |
| CN101356171A (zh) | 2005-11-15 | 2009-01-28 | 阿雷生物药品公司 | 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物 |
| GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| CN101490046A (zh) | 2006-05-09 | 2009-07-22 | 辉瑞产品公司 | 环烷基氨基酸衍生物及其药物组合物 |
| WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
| KR20090077914A (ko) * | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| KR20090067169A (ko) | 2006-09-11 | 2009-06-24 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 퀴나졸린 계열 ｅｇｆｒ 억제제 |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| CN101611041A (zh) | 2006-12-12 | 2009-12-23 | 武田药品工业株式会社 | 稠合杂环化合物 |
| CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| ME01461B (me) | 2008-02-07 | 2014-04-20 | Boehringer Ingelheim Int | Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju. |
| WO2009113560A1 (ja) | 2008-03-12 | 2009-09-17 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| PL2387563T5 (pl) | 2009-01-16 | 2023-03-13 | Exelixis, Inc. | Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2630134B9 (en) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
| MX2014003501A (es) | 2011-09-22 | 2014-07-22 | Pfizer | Derivados de pirrolopirimidina y purina. |
| CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| GEP20186879B (en) | 2014-04-30 | 2018-07-10 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| EP3795609B1 (en) | 2015-07-01 | 2024-04-03 | California Institute of Technology | Cationic mucic acid polymer-based delivery systems |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| US10828305B2 (en) | 2016-03-01 | 2020-11-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| EP3853220B1 (en) | 2018-09-18 | 2024-01-03 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| CN118715216A (zh) * | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| TW202530231A (zh) * | 2023-09-27 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹唑啉衍生物的可藥用鹽、其結晶形式及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| WO2000021955A1 (en) | 1998-10-08 | 2000-04-20 | Astrazeneca Ab | Quinazoline derivatives |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| CN1330640C (zh) * | 2000-06-22 | 2007-08-08 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
-
2001
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active Expired - Fee Related
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en not_active Ceased
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166D0/no unknown
-
2005
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20063831B (en) | Substituted bicyclic derivatives for treatment of abnormal cell growth | |
| GEP20022653B (en) | Processes and Intermediates for Preparing Anti-Cancer Compounds | |
| GEP20063799B (en) | Tropane derivatives useful in therapy | |
| GEP20033140B (en) | Substituted Bicyclic Derivatives Useful as Anticancer Agents | |
| MY127126A (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
| GEP20032896B (en) | 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| GEP20094675B (en) | Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain | |
| MXPA04000577A (es) | Derivados de dolastatina 10. | |
| AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
| AP9701041A0 (en) | Pyridylpyrrole compounds. | |
| AU3850600A (en) | Dalda analogs and their use | |
| BG103947A (en) | Derivatives of 9-oxymerythromycin | |
| GEP20063751B (en) | 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents | |
| DE602004011966D1 (en) | Heterocyclylverbindungen | |
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| MY133112A (en) | 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use | |
| NO20052182L (no) | Nye forbindelser | |
| TW200504030A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
| AP9801377A0 (en) | Tricyclic erythromycin derivatives. | |
| EP1109560A4 (en) | COMPOUNDS USEFUL AS AICARFT INHIBITORS | |
| TNSN02096A1 (en) | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| ATE310010T1 (de) | 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung |